Compare SXC & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | PRTA |
|---|---|---|
| Founded | 1960 | 2012 |
| Country | United States | Ireland |
| Employees | 848 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.8M | 501.2M |
| IPO Year | 2011 | 2013 |
| Metric | SXC | PRTA |
|---|---|---|
| Price | $6.59 | $9.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $9.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.9M | 496.3K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,600,300,000.00 | $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.30 | N/A |
| 52 Week Low | $5.52 | $4.32 |
| 52 Week High | $9.82 | $12.20 |
| Indicator | SXC | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 51.98 |
| Support Level | $6.57 | $9.07 |
| Resistance Level | $6.97 | $9.59 |
| Average True Range (ATR) | 0.29 | 0.38 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 80.49 | 64.30 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.